Cataracts Clinical Trial
Official title:
Distance, Intermediate and Near Visual Outcomes, Range of Vision and Patient Satisfaction After Bilateral Implantation of Different Multifocal IOLs
The purpose of this study is to evaluate vision at different distances (far (13 ft),
intermediate (2.0 ft) and near (13 to 15 in)) with and without the patient's glasses (if the
patient wears them), range of vision (the difference between the farthest distance and the
closest distance that the patient can comfortably read 20/25 of the near card), and patient
satisfaction (how satisfied/happy is the patient with their vision) following bilateral
implantation of different multifocal IOLs after routine phacoemulsification.
The patients are being asked to participate in this study because you have had cataract
surgery and have received one of the IOLs implanted: ReSTOR +4.0 D, ReSTOR +3.0 D,
Crystalens, and/or ReZoom. The investigator in charge of this study is Dr. Helga Sandoval.
This study is being conducted at Storm Eye Institute at the Medical University of South
Carolina and will involve approximately 50 volunteers.
STUDY DESIGN:
This is a prospective, non-randomized, unmasked pilot study.
1. SETTING:
Storm Eye Institute, Medical University of South Carolina, Charleston, SC
2. SUBJECTS
A total of 50 patients of both sexes and any race or ethnic background who underwent
uneventful routine bilateral cataract extraction and multifocal or accommodating intraocular
lens implantation will be included. Subjects will be divided in 5 groups of 10 subjects each
based on the IOL implanted as follows: ReSTOR +4.0 D, ReSTOR +3.0 D, Crystalens, ReZoom, and
Mix-and-match (patients implanted with ReSTOR in one eye and ReZoom in the fellow eye).
Assessment included a thorough medical history and a complete eye examination. The latter
will include ETDRS visual acuity at distance (4 mts), intermediate (60 cm) and near (33 or
40 cm accordingly to the lens, under photopic conditions) evaluated uncorrected and
best-corrected as well as distance-corrected near and intermediate visual acuity, , and
range of vision (uncorrected and distance-corrected); the previous tests will be done per
eye and both eyes (visual summation). Slit-lamp exam, eye dominance, stereopsis, pupil size
under photopic conditions, corneal topography and a satisfaction questionnaire will be
evaluated as well. A defocus curve will be performed as follows: a phoropter and a 100%
contrast ETDRS chart positioned 4 meters from the subject under photopic lighting conditions
will be used. Manifest refraction will be used to designate the zero (0) baseline. To begin
the testing, subjects will be defocused -5.00 D spherical correction from their best
distance correction (manifest refraction). The logMAR acuity at this refraction will be
recorded. Minus spherical power will be decreased in 0.50 D increments (i.e., -4.50 D, -4.00
D, -3.50 D, etc.) with logMAR acuity recorded at each change in correction until only the
best distance correction (manifest refraction) remains. In a further step, subjects will be
defocused +2.00 D spherical correction from the best distance correction (manifest
refraction) and the logMAR acuity will be recorded. Plus spherical power will be decreased
in 0.50 D increments (i.e., +1.50 D, +1.00 D, +0.50 D) with logMAR acuity recorded at each
change in correction until only the best distance correction (manifest refraction) remains.
;
Observational Model: Case-Only, Time Perspective: Retrospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT06005675 -
User Acceptability Evaluation of Pseudophakic Patients Previously Implanted With the TECNIS Odyssey IOL
|
||
Active, not recruiting |
NCT01382641 -
Show Improved Vision With the HOYA AF-1 Aspheric Intraocular Lens After Cataract Surgery
|
Phase 4 | |
Completed |
NCT01382823 -
Laser Cataract Surgery With the Femtosecond Laser Technology
|
Phase 4 | |
Completed |
NCT05991960 -
Evaluation of Real-World Data on the Performance of the TECNIS Odyssey™ IOL
|
||
Active, not recruiting |
NCT05574959 -
Clinical Investigation of the TECNIS® Next-Generation Intraocular Lens, Model DEN00V
|
N/A | |
Completed |
NCT02492659 -
Clinical Research of Femtosecond Laser-Assisted Cataract Surgery
|
N/A | |
Completed |
NCT01279031 -
Randomized Comparison of the Abbott WHITESTAR Signature System With Ellips Tranversal Ultrasound vs. the Alcon Infiniti With the Ozil Torsional Handpiece in Phacoemulsification: A Contralaterally-Controlled Trial
|
Phase 4 | |
Completed |
NCT01021761 -
A Comparison of Prostaglandin E2 (PGE2) Inhibition of Acuvail(Ketorolac 0.45%), Xibrom (Bromfenac 0.09%)and Nevanac (Nepafenac)in Patients Undergoing Phacoemulsification
|
Phase 4 | |
Completed |
NCT00999492 -
Selection of Aspheric Diffractive Multifocal Intraocular Lens (IOLS) Based on Corneal Wavefront
|
Phase 4 | |
Completed |
NCT01061463 -
Occupational Cataracts and Lens Opacities in Interventional Cardiology : the O'CLOC Study
|
N/A | |
Completed |
NCT01001806 -
A Comparison of Peak Aqueous Penetration of Acuvail (Ketorolac 0.45%), Xibrom (Bromfenac 0.09%), and Nevanac (Nepafenac 0.1%)in Patients Undergoing Phacoemulsification
|
Phase 4 | |
Completed |
NCT00542581 -
Acrysof Toric SN60T3corneal Astigmatism Between 0.75 and 1.00 D.
|
N/A | |
Completed |
NCT03708367 -
A Post-Market Evaluation of LipiFlow Treatment in Cataract Surgery Practice
|
N/A | |
Completed |
NCT05575063 -
Clinical Investigation of Healon EndoCoat Ophthalmic Viscosurgical Device (OVD)
|
N/A | |
Recruiting |
NCT05531292 -
PROOF-OF-CONCEPT STUDY FOR NEW INTRAOCULAR LENS, MODEL C0002
|
N/A | |
Completed |
NCT05058274 -
Clinical Results of a Monofocal Aspheric Bitoric Intraocular Lens With Plate Haptics in Hyperopic Eyes (HIPER-AT-TORBI)
|
||
Completed |
NCT05053399 -
Evaluation of the TECNIS Symfony® Toric Intraocular Lens
|
N/A | |
Recruiting |
NCT02639845 -
Eye Drop Application Monitor, Pilot Study
|
N/A | |
Completed |
NCT01684007 -
A Clinical Outcome Study of Two Multifocal Intraocular Lenses (IOL) in Cataract Patients
|
N/A | |
Completed |
NCT00827073 -
Comparison of Tetracaine 0.5% and Lidocaine 2% Jelly for Topical Phacoemulsification Cataract Surgery
|
N/A |